

Notice of Allowability

Application No.

10/762,769

Examiner

Ganapathirama Raghu

Applicant(s)

MELIS ET AL.

Art Unit

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 09/25/2006.
2. ☒ The allowed claim(s) is/are 1-3, 6 and 32.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date 9/25
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application
6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

DETAILED ACTION

Claims 1-3, 6 and 32 are pending in this application for examination.

Applicants' amendments and arguments filed on Oct. 25, 2006, have been fully considered and are deemed to be persuasive to overcome the rejections previously applied. Rejections and/or objections not reiterated from previous office action are hereby withdrawn.

Information Disclosure Statement

The information disclosure statement (IDS) submitted on 09/05/2006 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

Drawings

The drawings are accepted for examination purposes only.

EXAMINER'S AMENDMENT

An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it must be submitted no later than the payment of the issue fee.

Authorization for this Examiner's amendment was given in a telephone interview with Karl Bozicevic (Reg. No. 28,807) on 10/07/2006.

The application has been amended as follows:

In the claims:

In Claim 1,

Line 6, delete “hybridize” and replace with “ hybridizes under high stringency conditions, wherein said conditions are hybridization and/or washing conditions at 68⁰ C in 0.2. times. SSC or at 42⁰ C in 50% foramide, 4. times. SSC”.

In Claim 2,

Line 1, delete “The” and replace with “A”.

Line 7, delete “hybridize” and replace with “ hybridizes under high stringency conditions, wherein said conditions are hybridization and/or washing conditions at 68⁰ C in 0.2. times. SSC or at 42⁰ C in 50% foramide, 4. times. SSC”.

In Claim 6,

Line 6, delete “hybridize” and replace with “ hybridizes under high stringency conditions, wherein said conditions are hybridization and/or washing conditions at 68⁰ C in 0.2. times. SSC or at 42⁰ C in 50% foramide, 4. times. SSC”.

In claim 32,

Line 3, delete “algae algae” and replace with “algae”.

Line 3, delete “is is” and replace with “is”.

Line 6, delete “hybridize” and replace with “ hybridizes under high stringency conditions, wherein said conditions are hybridization and/or washing conditions at 68⁰ C in 0.2. times. SSC or at 42⁰ C in 50% foramide, 4. times. SSC”.

Art Unit: 1652

Allowable Subject Matter


Claims 1-3, 6 and 32 are allowed.

The following is an examiner's statement of reasons for allowance: Following a diligent search it was determined that the prior art neither teaches nor suggests a method of hydrogen gas generation comprising the steps of culturing genetically modified algae under suitable conditions wherein said genetically modified algae is genetically modified to disrupt the expression of a polypeptide with SEQ ID NO: 1 having sulfate permease activity by insertion of an antisense sequence which hybridizes to a portion of the encoding gene with DNA sequence of SEQ ID NO: 2 or the corresponding mRNA sequence of SEQ ID NO: 3. SEQ ID NOs.: 1, 2 and 3 were found to be novel and the prior art neither teaches nor suggests a genomic DNA sequence of SEQ ID NO: 2 or the corresponding mRNA of SEQ ID NO: 3 encoding for a polypeptide with SEQ ID NO: 1 having sulfate permease activity.

Any comments considered necessary by applicant must be submitted no later than the payment of issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance".

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ganapathirama Raghu whose telephone number is 571-272-4533. The examiner can normally be reached on 8 am to 4.30 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300 for regular communications and for After Final communications. Any inquiry of a general nature or relating to the status of the application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Ganapathirama Raghu, Ph.D.
Patent Examiner
Art Unit 1652
Nov. 07, 2006.


REBECCA E. PROITY
PRIMARY EXAMINER
GROUP 1800
1600